Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

by Yeming Wang MD, Dingyu Zhang MD, Prof Guanhua Du PhD, Prof Roghui Du MD, Prof Jianping Zhao MD, Prof Yang Jin MD

The Lancet - 29th April 2020 No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. Read full article

30th April 2020 • 0 comments

Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.

by Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, Krause PR, Longini IM, Mulangu S, Muyembe-Tamfum JJ, Nason MC, Smith PG, Wang R, Henao-Restrepo AM, De Gruttola V
2nd April 2020 • 0 comments

A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19

by Please see article webpage for full author details
18th March 2020 • 0 comments
15th February 2020 • 0 comments

Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans.

by Junbo Chen, Huachen Zhu, Peter W. Horby, Qianli Wang, Jiaxin Zhou, Hui Jiang, Liwei Liu, Tianchen Zhang, Yongli Zhang, Xinhua Chen, Xiaowei Deng, Birgit Nikolay, Wei Wang, Simon Cauchemez, Yi Guan, Timothy M. Uyeki, Hongjie Yu
16th January 2020 • 0 comments

Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients

by Janet T. Scott, Raman Sharma, Luke W. Meredith, Jake Dunning, Catrin E. Moore, Foday Sahr, Steve Ward, Ian Goodfellow, Peter Horby, RAPIDE-TKM Trial Team
16th January 2020 • 0 comments

Clinical REsearch During Outbreaks (CREDO) Training for Low- and Middle-Income Countries

by Nzelle Delphine Kayem, Amanda Rojek, Emmanuelle Denis, Alex Salam, Andreas Reis, Piero Olliaro, Peter Horby
2nd December 2019 • 0 comments
25th July 2019 • 0 comments
1st February 2019 • 0 comments

Clinical research networks and assessing pandemic severity

by Srinivas Murthy, Gail Carson, Peter Horby, Laura Merson, Steve Webb
18th December 2018 • 0 comments

Performance of different clinical trial designs to evaluate treatments during an epidemic

by Matthias Brueckner, Andrew Titman, Thomas Jaki, Amanda Rojek, Peter Horby

In the 2013-2016 west Africa outbreak of Ebola Virus Disease (EVD), most of the planned clinical trials failed to reach a conclusion within the time frame of the epidemic. We conduct a comprehensive evaluation of commonly used two- and multi-arm clinical trial designs based on real data, which was recorded during the 2013-16 EVD epidemic in west Africa

17th October 2018 • 0 comments
31st August 2018 • 0 comments